LSV Asset Management boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,301,055 shares of the biopharmaceutical company’s stock after acquiring an additional 35,028 shares during the period. LSV Asset Management’s holdings in Halozyme Therapeutics were worth $87,561,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in HALO. Root Financial Partners LLC bought a new position in Halozyme Therapeutics in the third quarter valued at about $25,000. Larson Financial Group LLC boosted its holdings in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the last quarter. Clearstead Advisors LLC boosted its holdings in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 265 shares during the last quarter. Penserra Capital Management LLC bought a new position in Halozyme Therapeutics during the third quarter worth about $52,000. Finally, Wexford Capital LP bought a new position in Halozyme Therapeutics during the third quarter worth about $70,000. Institutional investors own 97.79% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Morgan Stanley reduced their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. HC Wainwright raised their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Finally, Wells Fargo & Company raised their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.67.
Halozyme Therapeutics Trading Down 0.3%
NASDAQ HALO opened at $68.32 on Friday. The firm has a market cap of $8.10 billion, a P/E ratio of 24.58, a P/E/G ratio of 0.28 and a beta of 0.89. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The stock’s 50-day moving average is $65.74 and its 200-day moving average is $68.75. Halozyme Therapeutics, Inc. has a one year low of $51.06 and a one year high of $82.22.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current fiscal year.
Insider Transactions at Halozyme Therapeutics
In other news, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the sale, the director owned 38,498 shares of the company’s stock, valued at $2,443,853.04. This trade represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares in the company, valued at approximately $477,200.20. This represents a 55.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 120,482 shares of company stock valued at $8,200,842 over the last 90 days. 2.50% of the stock is owned by company insiders.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Stories
- Five stocks we like better than Halozyme Therapeutics
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
